HUMAN PHARMACOLOGY AND ABUSE POTENTIAL OF NALMEFENE

被引:24
作者
FUDALA, PJ
HEISHMAN, SJ
HENNINGFIELD, JE
JOHNSON, RE
机构
[1] National Institute on Drug Abuse, Addiction Research Center, Francis Scott Key Medical Center, Baltimore, MD
[2] Treatment Branch, NIDA, Addiction Research Center, Baltimore, MD 21224
关键词
D O I
10.1038/clpt.1991.32
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Nalmefene hydrochloride was administered to six male volunteers with histories of opitate abuse using a double-blind, randomized, Latin square design to determine if it produced typical morphine-like effects. A comparison of physiologic and subject- and observer-reported effects was made between morphine, 15 and 30 mg given intramuscularly; nalmefene, 25, 50, and 100 mg given orally; and placebo. Drowsiness or sleepiness was the most common drug effect reported after the administration of each treatment. Only morphine produced miosis and increased subject-reported euphoria and "drug liking." Neither drug increased Addiction Research Inventory subscale scores measuring dysphoria or sedation or produced changes on the Profile of Mood States questionnaire. Adverse effects reported only after the administration of nalmefene included agitation/irritability and muscle tension; these did not appear to be dose related. The data indicated that nalmefene did not produce typical morphine-like effects and has no apparent abuse potential.
引用
收藏
页码:300 / 306
页数:7
相关论文
共 24 条
[1]  
AITKENHEAD AR, 1984, ANESTHESIOLOGY, V61, P381
[2]   DURATION OF ANTAGONISTIC EFFECTS OF NALMEFENE AND NALOXONE IN OPIATE-INDUCED SEDATION FOR EMERGENCY DEPARTMENT PROCEDURES [J].
BARSAN, WG ;
SEGER, D ;
DANZL, DF ;
LING, LJ ;
BARTLETT, R ;
BUNCHER, R ;
BRYAN, C .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 1989, 7 (02) :155-161
[3]  
CROWLEY TJ, 1985, AM J PSYCHIAT, V142, P1081
[4]   NALMEFENE - INTRAVENOUS SAFETY AND KINETICS OF A NEW OPIOID ANTAGONIST [J].
DIXON, R ;
HOWES, J ;
GENTILE, J ;
HSU, HB ;
HSIAO, J ;
GARG, D ;
WEIDLER, D ;
MEYER, M ;
TUTTLE, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 39 (01) :49-53
[5]   NALMEFENE - SAFETY AND KINETICS AFTER SINGLE AND MULTIPLE ORAL DOSES OF A NEW OPIOID ANTAGONIST [J].
DIXON, R ;
GENTILE, J ;
HSU, HB ;
HSIAO, J ;
HOWES, J ;
GARG, D ;
WEIDLER, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 1987, 27 (03) :233-239
[6]  
FISHMAN J, 1973, J PHARMACOL EXP THER, V187, P575
[7]  
FRANCE CP, 1987, J PHARMACOL EXP THER, V242, P195
[8]  
FUDALA PJ, 1990, NIDA RES MG, V95, P451
[9]   PROLONGED BLOCKADE OF OPIOID EFFECT WITH ORAL NALMEFENE [J].
GAL, TJ ;
DIFAZIO, CA ;
DIXON, R .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1986, 40 (05) :537-542
[10]   NALTREXONE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC EFFICACY IN THE MANAGEMENT OF OPIOID DEPENDENCE [J].
GONZALEZ, JP ;
BROGDEN, RN .
DRUGS, 1988, 35 (03) :192-213